Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Debt / NOTE 2.250% 2/0
-
Market price (% of par)
-
85.63%
-
Total 13F principal
-
$627,730,524
-
Principal change
-
-$2,685,815
-
Total reported market value
-
$538,661,074
-
Number of holders
-
38
-
Value change
-
-$2,449,192
-
Number of buys
-
20
-
Number of sells
-
11
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 as of Q4 2024
As of 31 Dec 2024,
BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 was held by
38 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$627,730,524
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, Voya Investment Management LLC, BRAIDWELL LP, D. E. Shaw & Co., Inc., Weiss Asset Management LP, AMERIPRISE FINANCIAL INC, ARISTEIA CAPITAL, L.L.C., Davidson Kempner Capital Management LP, MACKAY SHIELDS LLC, and FMR LLC.
This page lists
38
institutional bondholders reporting positions
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.